|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schlesinger-Raab A, Mihaljevic AL, Egert
S, Emeny R, Jauch KW, Kleeff J, Novotny A, Nüssler NC, Rottmann M,
Schepp W, et al: Outcome of gastric cancer in the elderly: A
population-based evaluation of the Munich Cancer Registry. Gastric
Cancer. 19:713–722. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen L, Shan YS, Hu HM, Price TJ, Sirohi
B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of
gastric cancer in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berx G and van Roy F: Involvement of
members of the cadherin superfamily in cancer. Cold Spring Harb
Perspect Biol. 1:a0031292009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Virchow R: An address on the value of
pathological experiments. BMJ. 2:198–203. 1881. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luster AD: Chemokines - chemotactic
cytokines that mediate inflammation. N Engl J Med. 338:436–445.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Verbeke H, Struyf S, Laureys G and Van
Damme J: The expression and role of CXC chemokines in colorectal
cancer. Cytokine Growth Factor Rev. 22:345–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deng L, Chen N, Li Y, Zheng H and Lei Q:
CXCR6/CXCL16 functions as a regulator in metastasis and progression
of cancer. Biochim Biophys Acta. 1806:42–49. 2010.PubMed/NCBI
|
|
12
|
Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH,
Sun J, Yi Y, Shi JY, Shi GM, Ding ZB, et al: CXCR6 upregulation
contributes to a proinflammatory tumor microenvironment that drives
metastasis and poor patient outcomes in hepatocellular carcinoma.
Cancer Res. 72:3546–3556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim SS, Ruiz VE, Carroll JD and Moss SF:
Helicobacter pylori in the pathogenesis of gastric cancer and
gastric lymphoma. Cancer Lett. 305:228–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Fu LX, Zhu WL, Shi H, Chen LJ and Ye
B: Blockade of CXCR6 reduces invasive potential of gastric cancer
cells through inhibition of AKT signaling. Int J Immunopathol
Pharmacol. 28:194–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu X, Long Z, Cai H, Huang H, Shi Y and
Wang Y: Analysis of lymph node metastasis correlation with
prognosis in patients with T2 gastric cancer. PLoS One.
9:e1051122014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao G, Wang X and Wang J, Zu L, Cheng G,
Hao M, Sun X, Xue Y, Lu J and Wang J: CXCL16/CXCR6 chemokine
signaling mediates breast cancer progression by pERK1/2-dependent
mechanisms. Oncotarget. 6:14165–14178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mir H, Singh R, Kloecker GH, Lillard JW Jr
and Singh S: CXCR6 expression in non-small cell lung carcinoma
supports metastatic process via modulating metalloproteinases.
Oncotarget. 6:9985–9998. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Lu Y, Wang J, Koch AE, Zhang J and
Taichman RS: CXCR6 induces prostate cancer progression by the
AKT/mammalian target of rapamycin signaling pathway. Cancer Res.
68:10367–10376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gooden MJ, Wiersma VR, Boerma A, Leffers
N, Boezen HM, ten Hoor KA, Hollema H, Walenkamp AM, Daemen T,
Nijman HW, et al: Elevated serum CXCL16 is an independent predictor
of poor survival in ovarian cancer and may reflect pro-metastatic
ADAM protease activity. Br J Cancer. 110:1535–1544. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Held-Feindt J, Rehmke B, Mentlein R,
Hattermann K, Knerlich F, Hugo HH, Ludwig A and Mehdorn HM:
Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes
growth of human schwannomas. Glia. 56:764–774. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stockinger A, Eger A, Wolf J, Beug H and
Foisner R: E-cadherin regulates cell growth by modulating
proliferation-dependent beta-catenin transcriptional activity. J
Cell Biol. 154:1185–1196. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valdés F, Alvarez AM, Locascio A, Vega S,
Herrera B, Fernández M, Benito M, Nieto MA and Fabregat I: The
epithelial mesenchymal transition confers resistance to the
apoptotic effects of transforming growth factor Beta in fetal rat
hepatocytes. Mol Cancer Res. 1:68–78. 2002.PubMed/NCBI
|
|
23
|
Klymkowsky MW and Savagner P:
Epithelial-mesenchymal transition: A cancer researcher's conceptual
friend and foe. Am J Pathol. 174:1588–1593. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu M, Marsters S, Ye X, Luis E, Gonzalez L
and Ashkenazi A: E-cadherin couples death receptors to the
cytoskeleton to regulate apoptosis. Mol Cell. 54:987–998. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uttamsingh S, Bao X, Nguyen KT, Bhanot M,
Gong J, Chan JL, Liu F, Chu TT and Wang LH: Synergistic effect
between EGF and TGF-beta1 in inducing oncogenic properties of
intestinal epithelial cells. Oncogene. 27:2626–2634. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morali OG, Delmas V, Moore R, Jeanney C,
Thiery JP and Larue L: IGF-II induces rapid beta-catenin relocation
to the nucleus during epithelium to mesenchyme transition.
Oncogene. 20:4942–4950. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanaka T, Bai Z, Srinoulprasert Y, Yang
BG, Hayasaka H and Miyasaka M: Chemokines in tumor progression and
metastasis. Cancer Sci. 96:317–322. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Corso G, Marrelli D and Roviello F:
Familial gastric cancer and germline mutations of E-cadherin. Ann
Ital Chir. 83:177–182. 2012.PubMed/NCBI
|
|
29
|
Becker KF, Atkinson MJ, Reich U, Becker I,
Nekarda H, Siewert JR and Höfler H: E-cadherin gene mutations
provide clues to diffuse type gastric carcinomas. Cancer Res.
54:3845–3852. 1994.PubMed/NCBI
|
|
30
|
Corso G, Carvalho J, Marrelli D, Vindigni
C, Carvalho B, Seruca R, Roviello F and Oliveira C: Somatic
mutations and deletions of the E-cadherin gene predict poor
survival of patients with gastric cancer. J Clin Oncol. 31:868–875.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hazan RB, Qiao R, Keren R, Badano I and
Suyama K: Cadherin switch in tumor progression. Ann NY Acad Sci.
1014:155–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
